The share price of Aposense Ltd. (TASE: APOS) doubled in morning trading today, after announcing that it had obtained a US patent on its ATT-11T molecule for the treatment of colon, lung, and ovarian cancers. The patent covers the molecule's assembly, and will expire on November 22, 2030.
Aposense developed ATT-11T, its leading product, together with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA). The molecule is a conjugate of the active ingredient in irinotecan (SN-38) and proprietary Aposense molecules, which extend irinotecan's effectiveness and reduce its toxicity.
ATT-11T has been found in preclinical trials to have superior efficacy than irinotecan in terms of the amount of the active ingredient in the tumor tissue and longer time in the bloodstream, imparting it an edge over current cancer drugs by extending the effectiveness of the treatment.
Aposense CEO Dr. Miri Ben-Ami said, "Approval of the patent is an important milestone for Aposense, in view of the company's progress in therapeutics, where ATT-11T is our flagship product. We plan to file a pre-investigational new drug (IND) with the US Food and Drug Administration (FDA) for further development of the drug, including clinical trials. The company's patent strategy is intended to provide multilayered patent protection for its products. We believe that the patent which was approved is proof of the company's patent standing and its proprietary platform."
Published by Globes [online], Israel business news - www.globes-online.com - on June 27, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013